• Latest Posts

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Results from 45% of Clinical Trials are kept Secret

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016


Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

Get to Know the Top 50 Women in the UK’s Biotech Scene

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO